New Flower, Lower Prices, Same Great Team: Retiring Daily Deals for Better Everyday Savings
Big changes are blooming at NuVue Pharma — and it’s all good news for your wallet. We’ve heard your feedback and looked closely at how
The Drug Enforcement Agency has been in conversation with the FDA on medical marijuana research and its status as a Schedule 1 drug.
A letter from the DEA dated April 4th (and released by the Huffington Post April 5th) addressed recent questions from several of the Democratic Senators cosponsoring The Compassionate Access, Research Expansion and Respect States (CARERS) Act, a proposition introduced in March of 2015 to shield from federal law those abiding by their state marijuana regulations, expand research, and make marijuana a Schedule II drug. While that bill is stuck in Senate limbo, the DEA may be looking to make that schedule change anyway.
The bombshell in the letter isn’t that the DEA is considering a recommendation on rescheduling marijuana (mainly because there is no indication what that recommendation will be) but that there are “hopes to release its determination in the first half of 2016.” In addition to marijuana, CBD is being evaluated for scheduling determination as an isolated drug.
A Schedule 1 Drug by definition has no medical benefit (as well as a “high potential for abuse”; therefore, changing its schedule has always depended on medical research. In addition to an inventory of the current marijuana available for federal research at the University of Mississippi, the letter discusses the potential to “increase the number of permits for the bulk manufacture of marijuana for research purposes,” in anticipation of the need for additional study and genetic variety in federal research.
It looks like the DEA is interested in expanding federal research beyond a single grow facility and 265 registered researchers. Looking at the breakdown of the marijuana available for research (the facility produces Placebo and Low, Medium, High and Very High THC varieties, each of which contain strains with very low to very high CBD content), it’s not hard to see that genetic variety is sorely needed in order to expand medical study to encompass each component of the endocannabinoid system.
The long-overdue removal of marijuana from Schedule 1 would signal the federal acknowledgement of marijuana as medicine and turn a major page in the story of medical cannabis. At NuVue Pharma, we’re watching to see if that day is coming in 2016.
Big changes are blooming at NuVue Pharma — and it’s all good news for your wallet. We’ve heard your feedback and looked closely at how
Despite over half of U.S. states legalizing cannabis for medical or recreational use, federal legalization remains elusive. While public opinion strongly favors reform and the
As the U.S. cannabis industry continues to thrive, driven by expanding state-level legalization and the growth of both medical and adult-use markets, new questions are
Day 1: Clue 1: This game is no trick, to find the Easter Egg you must be quick, get too close today, and I might
In a landmark shift for Colorado Springs, NuVue Pharma is set to commence recreational cannabis sales on April 15, 2025. This development follows a series
Colorado’s cannabis industry is poised for significant changes with the introduction of House Bill HB25-1209, titled “Marijuana Regulation Streamline.” This bill aims to enhance regulatory
In a pivotal move following the 2025 election, voters in Colorado Springs approved the legalization of recreational marijuana sales, marking a significant shift in
The wellness industry has witnessed a groundbreaking addition with the launch of Tru Lube Personal Massage Oil, a premium product infused with cannabinoids derived
Cannabis is a plant revered for its rich tapestry of cannabinoids, terpenes, and flavonoids, all of which contribute to its unique therapeutic and recreational properties.
Pueblo, Colorado, has been at the forefront of the state’s cannabis industry since recreational marijuana was legalized in 2014. Over the past decade, the